secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001104659-25-021371
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia Q4 2024: BioEnvelope sales +18% to $2.7M; EluPro pilot launch gains traction; net loss $9.1M
--------------------------------------------------------------------------------

- Q4 BioEnvelope sales $2.7M (+18% YoY); overall net sales $5.5M (-7% YoY) due to SimpliDerm and cardiovascular declines.
- EluPro accounted for over 30% of BioEnvelope sales in Q4; 67 approved accounts and ~100 actively ordering.
- Q4 GAAP gross margin improved to 42.5% (from 36.2%); adjusted gross margin 58.1% (from 50.6%).
- Full year 2024 net loss from continuing ops $54.1M vs $41.2M; adjusted EBITDA loss narrowed to $12.9M from $14.4M.
- Year-end cash $13.2M; raised ~$15M gross proceeds in February 2025 registered direct offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925021371/0001104659-25-021371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925021371/tm258477d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-021371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer